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The heart has both the greatest caloric needs and the most robust oxidation of fatty acids (FAs). Under path-
ological conditions such as obesity and type 2 diabetes, cardiac uptake and oxidation are not balanced and
hearts accumulate lipid potentially leading to cardiac lipotoxicity. We will first review the pathways utilized by
the heart to acquire FAs from the circulation and to store triglyceride intracellularly. Then we will describe
mouse models in which excess lipid accumulation causes heart dysfunction and experiments performed
to alleviate this toxicity. Finally, the known relationships between heart lipid metabolism and dysfunction
in humans will be summarized.Introduction
Although the heart is far and away the most energy-requiring
organ of the body, studies of cardiac lipidmetabolism, especially
in vivo, are relatively scarce compared to investigations in
adipose tissue or liver. In adult fasting mammals, 60%–80% of
cardiac energy metabolism relies on the oxidation of fatty acids
(FAs) with glucose, lactate, and ketones providing substrates for
the remainder (Neely et al., 1972). The adult heart, however, has
the ability to switch to different substrates for ATP generation de-
pending on feeding, hormonal status, and overall nutritional
supply as characterized by the Randle cycle (Hue and Taegt-
meyer, 2009). Of note, there are major species differences with
mice relying more on glucose, lactate, and ketone bodies, and
less on FAs (30%–40% from fat) (Stanley et al., 2005; Stowe
et al., 2006). The fetal heart operates under low oxygen pressure
and primarily depends on glucose and lactate for ATP genera-
tion, whereas the adult heart utilizes FAs but conserves the ability
to switch other substrates. Older animals and humans use rela-
tively fewer FAs and more glucose.
The heart avidly acquires lipids both from circulating nonester-
ified (free) fatty acids (FFAs) and esterified FAs bound to lipopro-
teins (Figure 1A). Observations made studying arterial venous
differences in substrate concentrations showed that esterified
FAs were a major source of lipids for the human heart (Ballard
et al., 1960). More recent methods to study heart lipid metabo-
lism have relied on tracers of FFAs in, for example, isolated
perfused hearts. These studies quantify conversion of FFAs to
CO2 and TCA cycle intermediates under a variety of experi-
mental conditions. In vivo studies can assess the uptake and
loss of tracers from the heart. Although the heart can synthesize
lipoproteins as it expresses both apoB and microsomal triglyc-
eride transfer protein (Bartels et al., 2009; Nielsen et al., 1998),
under most circumstances, the heart probably does not rese-
crete appreciable amounts of glucose or lipids, and the uptake
should indicate oxidation plus a relatively small amount of
substrate that is stored and a small amount of substrate used
for structural requirements of the cell.
In some situations the heart adjusts to maintain lipid homeo-
stasis. Increases inwork load (Goodwin et al., 1998) andmyocar-
dial ischemia (Lopaschuk et al., 2010) cause a rapid switch from
fat to glucose utilization for ATP generation. This finding has
led to several animal studies showing that administration ofcompounds that reduce FA oxidation protect the heart from
the consequences of ischemia and ischemia-reperfusion injury
(Goodwin et al., 1998; Lopaschuk et al., 2010). This is presumed
to be due to reduced oxygen requirements for non-FA
substrates. Deleterious effects of cardiac ischemia could be
due in part to excess cardiac lipid accumulation via the VLDL
receptor (Perman et al., 2011). Similarly, in another mousemodel
of cardiomyocyte death adiponectin-induced activation of a ce-
ramidase and reduction of ceramide was beneficial (Holland
et al., 2011). Therefore, abnormal regulation of lipid uptake or
its intracellular metabolism might play an important role in heart
diseases other than metabolic dilated cardiomyopathy.
An imbalance between FA uptake and oxidation leads to accu-
mulation of long-chain FAs that are incorporated into triglyceride
(TG) and phospholipids, as well as a multitude of other lipid
subspecies. Although TG is themost easily detected, other lipids
are more likely to be toxic. Diacylglycerols (DAGs) and ceram-
ides are signaling lipids that are thought to be toxic when their
intracellular concentrations are increased. Defective mitochon-
drial FA oxidation could lead to accumulation of medium-chain
acyl carnitines (Koves et al., 2008), another possible toxin.
Finally, saturated long-chain FAs, most notably palmitate, are
associated with toxicity in cells either because of their direct
actions or their incorporation into phospholipids (Borradaile
et al., 2006).
Sources of Heart Lipids
All tissues obtain lipids from FFAs associated with albumin, lipo-
proteins, and de novo synthesis (Figure 1A). Although de novo
synthesis is thought to play aminor role in heart lipidmetabolism,
a recent study of deletion of FA synthetase in heart showed that
de novo synthesis is important to maintain cardiac function
during aortic constriction and aging (Razani et al., 2011). Loss
of lipoprotein lipase (LpL)-derived lipids leads to increased
glucose uptake in mouse hearts (Augustus et al., 2004). In hu-
mans, deficiency in CD36 is associated with increased glucose
uptake (Fukuchi et al., 1999). CD36 appears most important in
the setting of lower concentrations of FFAs (Coburn et al.,
2000). Therefore, it is not surprising that when large amounts
of FFA are generated during hydrolysis of large TG-rich lipopro-
teins like chylomicrons, heart uptake of lipids appears to be
exclusive of this receptor (Bharadwaj et al., 2010). Lipolysis ofCell Metabolism 15, June 6, 2012 ª2012 Elsevier Inc. 805
Figure 1. Regulation of Cardiomyocyte
Lipid Storage
(A) Fatty acids esterified as triacylglycerol (TG)
within lipoproteins require hydrolysis by lipopro-
tein lipase (LpL) associated with proteoglycans
and GPIHBP1 on the luminal surface of endothelial
cells. Angiopoietin-like protein 4 (ANGPTL4) is an
LpL inhibitor. Nonesterified fatty acids (FFA)
associated with albumin likely are internalized by
membrane transporters such as CD36. These
lipids must cross the endothelial barrier; how this
occurs is unclear.
(B) Within the cardiomyocytes the FAs are esteri-
fied to CoA and either stored in the lipid droplet
(LD) or used for energy. At least four lipid-droplet
proteins (perilipins; PLINs) are expressed in the
heart. The lipid droplet supplies some oxidized
FAs via the actions of adipose triglyceride lipase
(ATGL)/desnutrin and hormone-sensitive lipase
(HSL). CGI58 is the ATGL coactivator. ATGL and
LpL actions both provide ligands for PPAR
activation.
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such as cholesteryl esters and retinyl esters into the heart (Bhar-
adwaj et al., 2010).
Cardiac Storage of Lipids
Excess lipid, especially TG, beyond that needed for cellular
structures and ATP generation, is stored in lipid droplets
(Figure 1B). Within the heart, there normally is little droplet accu-
mulation, suggesting that uptake and oxidation are finely regu-
lated. Lipid droplets are found in hearts of patients with diabetes
and metabolic syndrome (Marfella et al., 2009; McGavock et al.,
2007; Sharma et al., 2004) and in those of high-fat diet-fed
rodents and genetically altered mice (see below and Table 1).
In addition, after an overnight fast, lipid droplets appear in the
hearts of wild-type mice (Suzuki et al., 2002).
Lipid-droplet protein makeup in the heart is different from that
of adipocytes. In the heart, there is minimal expression of peril-
ipin (Plin1). However, the other major lipid droplet proteins, adi-
pophilin/adipose differentiation-related protein (ADRP/Plin2),
tail-interacting protein 47 (Tip47/Plin3), S3-12 (Plin4), and
OXPAT/myocardial LD protein/lipid-storage droplet protein 5
(Plin5) are all expressed in the heart (Paul et al., 2008). Plin2
expression might be most upregulated in some forms of lipotox-
icity and be important for nontoxic lipid storage (Son et al., 2007).
Plin5 appears to regulate TG oxidation by approximating lipid
droplets and mitochondria (Bosma et al., 2011; Wang et al.,
2011). Of these droplet proteins, only Plin2 has been deleted,
and chow-fed Plin2/ mice do not have an obvious cardiac
phenotype (Chang et al., 2006). Thus, knowledge of how and
whether these proteins, and probably others, modulate heart-
lipid accumulation and TG oxidation is likely to be forthcoming.
Lipid-droplet turnover is regulated by lipid-droplet-associated
proteins, intracellular lipases, and acyltransferases (Meex et al.,
2009). Cardiac myocytes and skeletal myocytes have similar806 Cell Metabolism 15, June 6, 2012 ª2012 Elsevier Inc.regulatory pathways that govern lipid
metabolism. Lipid-droplet TG can be
hydrolyzed by adipose triglyceride
lipase/desnutrin (ATGL) and hormone-sensitive lipase (HSL), both of which are expressed in the heart.
In the adipose tissue, insulin inhibits lipolysis, whereas catechol-
amines, thyroid hormone, and glucagon stimulate lipolysis.
Whether similar regulation occurs in the heart is not known at
present.
The roles of lipolytic enzymes in the heart have been studied
using genetically modified mice (Table 1). Lipid-droplet accumu-
lation in overnight fasting mice is prevented by overexpression
of HSL (Suzuki et al., 2001). In the total HSL knockout mouse,
cardiac TG lipase activity was decreased, but cardiac TG was
not dramatically changed and there was no overt cardiac
phenotype (Osuga et al., 2000). In contrast, Atgl/ mice have
markedly reduced cardiac TG lipase activity, massive lipid accu-
mulation, and severe cardiomyopathy (Haemmerle et al., 2006).
In part, this is likely due to a defect in the hydrolysis of TG that
the heart stores for potential energy (Banke et al., 2010). Treat-
ment of Atgl/ mice with a PPARa agonist corrected the
cardiac phenotype (Haemmerle et al., 2011). Therefore, the
excess accumulation of TG in the Atgl/ hearts was at least
partially due to increased lipid storage secondary to defective
FA oxidation. A less dramatic phenotype but one also associ-
ated with decreased FA oxidation activation occurred with
cardiac deletion of acyl CoA synthetase 1 (Ellis et al., 2011).
This study and another from this group (Ellis et al., 2010) suggest
that PPAR activation is via a product of the CoA synthetase
reaction.
Recent studies have elucidated the role of autophagy in
hepatic TG lipolysis. In the rodent heart, autophagy has been
investigated as a stress-response mechanism in myocardial
infarction and pressure-induced cardiac hypertrophy. Fasting
induces autophagy in the heart (Ogata et al., 2010), yet charac-
terization of autophagy in the heart has not focused on lipid
metabolic derangements. Inducible heart-specific autophagy
knockouts develop cardiomyopathy (Nakai et al., 2007); whether
Table 1. Models of Cardiac Lipotoxicity
Cardiac Lipotoxicity Reference Corrections Reference
MHC-ACS1 (Chiu et al., 2001) Leptin treatment
X MHC-DGAT1
a-Lipoic acid
(Lee et al., 2004, 2006)
(Liu et al., 2009)
MHC-FATP1 (Chiu et al., 2005)
Heart-specific PPARd knockout (Cheng et al., 2004)
MHC-PPARa (Finck et al., 2002) X heart-specific LpL ko
X CD36/
Medium-chain triglyceride diet
(Duncan et al., 2010)
(Yang et al., 2007)
(Finck et al., 2003)
MHC-PPARg (Son et al., 2007) X PPARa knockout (Son et al., 2010)
Leptin deficiency (ob/ob) (Christoffersen et al., 2003)
(Barouch et al., 2003)
Leptin infusion (Barouch et al., 2003)
ATGL knockout (Schweiger et al., 2006) PPARa agonists (Haemmerle et al., 2011)
MHC-LpLGPI (Yagyu et al., 2003) Ceramide synthesis inhibition (Park et al., 2008)
MHC-LPL X PPARa/ (No¨hammer et al., 2003)
MHC-GLUT1 on HFD (Yan et al., 2009)
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found in other organs (Singh et al., 2009), is unknown.
Creation of Cardiac Lipotoxicity in Mice
A number of reasons for the association between diabetes and
heart dysfunction in the absence of underlying vascular disease
have been proposed; one of these is excess accumulation of
lipids in cardiomyocytes (Boudina and Abel, 2007). This
possible cause of cardiomyopathy has been modeled by
creating genetically modified animals in which lipid accumula-
tion without generalized metabolic derangements leads to
contractile impairment (Figure 2, Table 1). These animals have
an imbalance between lipid uptake and oxidation due to either
increased lipid uptake or decreased oxidation. Increased
uptake of circulating FFAs or lipoprotein-derived lipids as
occurs with transgenic expression of LpL (No¨hammer et al.,
2003; Yagyu et al., 2003) leads to reduced heart function. Trans-
genic mice with cardiomyocyte-specific expression of FA trans-
port protein 1 (Chiu et al., 2005) and acyl CoA synthetase 1 (Chiu
et al., 2001) are thought to have increased FFA uptake or trap-
ping in the heart leading to heart failure. PPAR transcription
factors drive FA oxidation; however, the increased lipoprotein-
lipid uptake in PPARa transgenic mice (Duncan et al., 2010)
must exceed the increased FA oxidation found in this model
because the hearts have excess stored lipids. Cardiomyocyte
PPARg overexpression leads to a similar phenotype (Son
et al., 2007). Surprisingly, PPARd expression does not lead to
cardiac dysfunction or toxicity (Burkart et al., 2007), presumably
because upregulation of the LpL inhibitor angiopoietin-like
protein 4 (Angptl4) prevents excess lipid uptake (Georgiadi
et al., 2010).
LpL is the key enzyme for distribution of circulating lipids
between organs. Perhaps the most clinically relevant model of
cardiac lipotoxicity is one created by accident. Wang et al.
deleted LpL using a skeletal muscle-specific promoter (Wang
et al., 2009). The mice were meant to model physically inactive
humans who also have reduced muscle LpL and FA oxidation.
These mice have increased insulin sensitivity in skeletal muscle,
as would be expected with reduced FA uptake, but developinsulin resistance in the heart, often a precursor of eventual heart
dysfunction.
Reduced lipid oxidation can also lead to lipid accumulation
and cardiomyopathy. This occurs with cardiac-specific
knockout of PPARd (Cheng et al., 2004) and a cardiac LpL trans-
gene crossed onto the Ppara/ background (No¨hammer et al.,
2003). Similarly heart dysfunction with excess lipid accumulation
is found when heart-specific GLUT1 overexpressing mice
are placed on a high-fat diet (Yan et al., 2009). In contrast,
when these animals eat chow, their function is improved in the
presence of hypertension (Liao et al., 2002). So, in some situa-
tions, dietary-driven lipid uptake—a likely accompaniment of
our western diet—needs to be added to create a lipotoxic
environment.
Perhaps of most interest for understanding heart-lipid metab-
olism and toxicity are the situations where reduced FA oxidation
does not lead to lipid accumulation. In many cases the reason for
this has not been investigated, but we would presume that there
is a compensation, such as a reduction in lipid uptake. This
occurs with genetic or pharmacologic deficiency of DGAT1,
which markedly reduces CD36 expression (Liu et al., 2011).
Pharmacologic FA oxidation inhibitors proposed for reduction
of ischemia (Lopaschuk et al., 2010) and genetically engineered
defects in FA oxidation (Dyck et al., 2006) would be expected
to also create cardiac lipid accumulation and toxicity. That this
does not occur indicates the existence of some processes
that balance reduced oxidation or that lead to nontoxic lipid
storage.
Lipid Stores and the Causes of Toxicity
Although the most obvious and easiest to measure accumulated
lipid is TG, TG itself might not be toxic. Consistent with cellular
studies (Listenberger et al., 2003), several experimental situa-
tions have dissociated TG accumulation from toxicity. Total
body knockout of HSL was associated with more refeeding TG
accumulation, but no toxicity (Suzuki et al., 2009). A cross of
the PPARg transgene onto the Ppara/ background corrected
toxicity without reducing heart TG, ceramide, or DAGs, but redis-
tributed the lipids into larger droplets (Son et al., 2010).Cell Metabolism 15, June 6, 2012 ª2012 Elsevier Inc. 807
Figure 2. Lipotoxicity Is Created by an Imbalance of Lipid Uptake
and Oxidation
Genetically modified mice have been created that have either increased lipid
uptake or decreased oxidation. Uptake occurs via the cell-surface molecules
lipoprotein lipase (LpL) and perhaps the FA transporter CD36 and/or FATPs.
More FAs are ‘‘trapped’’ by complexing to CoA. Stored triglyceride accumu-
lates with defective hydrolysis due to deletion of ATGL. Two interventions, loss
of PPARd and high-fat feeding in mice overexpressing Glut1, lead to reduced
lipid oxidation. Transgenic expression of PPARa and PPARg, which induce
lipid oxidation genes, also cause lipid accumulation, presumably because
uptake exceeds oxidation.
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been made that excess reliance on FA oxidation is harmful, even
under nonischemic conditions. Some experimental data suggest
the opposite. High-fat diets, which usually increase reliance on
FA oxidation, may be beneficial in the setting of nonischemic
heart failure (Okere et al., 2006b). Increased FA oxidation has
been found with a Pparg transgene crossed onto the Ppara/
background (Son et al., 2010), Dgat1 transgenic expression
(Liu et al., 2009), and most recently with PPARa agonist treat-
ment of Atgl/ mice (Haemmerle et al., 2011), all of which
improve heart failure.
Heart-lipid content can also be increased by nongenetic
means. While in some ways these models may more closely
reflect human pathology, they suffer from the many other
systemic effects of overnutrition or diabetes. In addition, the
heart phenotypes are relatively mild compared to those found
with genetic modifications. Mice fed a high-fat diet rapidly
develop cardiac insulin resistance, suggesting that lipid accu-
mulation rapidly causes changes in heart metabolism allowing
it to rely more on FAs as its fuel (Park et al., 2005). But the effects
of high fat on cardiac function are mixed. Hypertensive rats fed
a 60% fat diet had less left ventricular hypertrophy and systolic
dysfunction than animals fed 10% fat (Okere et al., 2006b). Simi-
larly, rats fed a high-fat diet appeared to compensate by
increasing FA oxidation, whereas those eating a lower fat but
higher carbohydrate western diet developed dysfunction (Wilson
et al., 2007). Not all fats are equal. Saturated FA-rich diets alone
increased cardiomyocyte apoptosis, perhaps due to accumula-
tion of ceramide (Okere et al., 2006a). In contrast, medium-chain
FAs are protective against cardiac dysfunction in some situa-
tions (Irie et al., 2003; Labarthe et al., 2005).
Other pharmacologic and genetic alterations change heart TG
content. Using oxfenicine to block CPT-1, mice fed a diet en-
riched in long-chain saturated FA accumulated TG but had no808 Cell Metabolism 15, June 6, 2012 ª2012 Elsevier Inc.changes in left ventricular dimensions or systolic function, while
PPAR-regulated genes were upregulated (Okere et al., 2007).
Ob/ob and db/db mice have increased heart FA oxidation that
develops prior to hyperglycemia (Buchanan et al., 2005). Eventu-
ally these mice develop decreased contractile function (Boudina
et al., 2005).
Correction of Lipotoxic Heart Disease
A role of animal models is to test interventions that might be
beneficial in human disease. Genetic approaches define targets,
which might be amenable to pharmacologic or dietary interven-
tions. Although a common underlying theme of lipotoxic cardio-
myopathy is that it is created via an alteration in lipidmetabolism,
a single underlying toxic lipid species might not be causative in
all cases. Thus, interventions in one model might not prove to
be beneficial in another. Similarly, the genetic and dietary varia-
tion amongst humans might also lead to multiple causes of
cardiomyopathy associated with lipid accumulation.
Altering the amount or type of FAs acquired by the heart will
prevent toxicity both in genetic and dietary models of lipid
toxicity (Table 1). Deletion of either CD36 or LpL corrected the
cardiac toxicity associated with cardiomyocyte overexpression
of PPARa (Duncan et al., 2010; Yang et al., 2007). CD36 deletion
was also reported to improve heart function in aged mice that
were eating a diet enriched in medium-chain FAs (Koonen
et al., 2007). Medium-chain FA-rich diets were also beneficial
in PPARa transgenic mice (Finck et al., 2003), presumably
because of a reduction in saturated long-chain fat-enriched lipid
accumulation. Other methods to reduce heart lipid content may
also correct or prevent toxicity. The approaches to do that have
included transgenic expression of HSL to increase lipolysis of
stored lipids (Ueno et al., 2008), reduced expression glycerol-
3-phosphate acyltransferase-1 to decrease TG accumulation
(Lewin et al., 2008), and overexpression of apolipoproteinB to
increase cardiac lipid secretion (Yokoyama et al., 2004).
A targeted approach to modify one lipid species would seem
to be an ideal way to both treat the disease and also define the
toxic lipid species. Such an approach was taken by reducing ce-
ramide levels in LpL-overexpressingmice using the serine palmi-
toyl transferase (SPT) inhibitor myriocin and SPT-deficient mice
(Park et al., 2008). A similar attempt to specifically modify
another toxic lipid, DAG, was attempted by overexpressing
diacylglycerol acyl transferase 1 (DGAT1) in cardiomyocytes.
Although this intervention reduced DAG levels and heart
dysfunction, ceramide was also reduced (Liu et al., 2009). This
study suggests that alteration of a single lipid species in the heart
might be difficult due to the interrelationship of lipid-metabolism
pathways.
Evidence that HumanCardiac Dysfunction Is Associated
with Excess Lipid
Unger has speculated that heart dysfunction due to excess
accumulation of lipid, termed lipotoxic cardiomyopathy or fatty
heart, is an unappreciated clinical entity (Szczepaniak et al.,
2007). While this claim is controversial due to the confounding
effects of classical risk factors coexisting in obese people such
as physical inactivity, hypertension, hyperlipidemia, and dia-
betes, cardiac lipotoxicity alone or in combination with other
risk factors might be an additional pathophysiologic abnormality
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betes, metabolic syndrome, and obesity accumulate excess in-
tramyocardial lipid and exhibit decreased systolic or diastolic
function (Ernande et al., 2010; Ng et al., 2009). Clinical data
show that both obesity and diabetes markedly increase risk of
heart failure even in the absence of ischemic vascular disease
(Kannel et al., 1974; Regan et al., 1977). The underlying molec-
ular mechanisms could be either increased lipid uptake or
impaired mitochondrial oxidative function leading to accumula-
tion of TGs and toxic lipid species such as ceramides, which
cause myocyte loss through apoptosis, induction of iNOS, and
prohypertrophic signaling (Unger and Orci, 2001). More recent
data have, however, found conflicting results with TG accumula-
tion being detectable both in patients with and without systolic
and diastolic cardiac dysfunction, and it has been claimed that
levels of TG are rather a phenomenon defined by the type of
specific cardiomyopathy and not directly related to cardiac
dysfunction itself (Ernande et al., 2010; Kankaanpa¨a¨ et al.,
2006; Nakae et al., 2010; Ng et al., 2009). Therefore, the specific
form of excess cardiac lipid compounds (TG, ceramides, DAG),
their cellular compartmentalization and storage form (lipid drop-
lets), and the specific cause of heart failure are likely to determine
the importance of lipotoxicity in human disease.
Studies of human cardiac function and metabolism rely on
imaging methods that are relatively noninvasive. PET scanning
assesses the uptake of various tracers into the heart. This tech-
nique is well standardized for both glucose and FFA uptake.
Myocardial PET imaging has consistently shown increased
FFA uptake and oxidation, as well as impaired glucose uptake,
in diabetic patients with normal systolic and mildly impaired dia-
stolic function (Rijzewijk et al., 2009). More recently, magnetic
resonance protocols have been developed to track TG metabo-
lism such as 1H magnetic resonance spectroscopy (MRS)
(O’Connor et al., 2011).
Although hypertension and coronary artery disease are
common in obese and diabetic patients, reduced heart function
independent of these underlying disorders may relate to toxic-
ities from excess metabolic substrates and defective insulin
action. Some studies in patients with obesity and diabetes corre-
lated TG accumulation with left ventricular hypertrophy (Herrero
et al., 2006; Szczepaniak et al., 2003). More TG has also been
found in failing hearts of patients with obesity or diabetes at
the time of transplantation (Sharma et al., 2004). Similarly,
a modest correlation exists between plasma FFA levels and
reduced diastolic function (Leichman et al., 2006). Limited data
suggest that weight loss leads to reduced cardiac TG levels
and reduced FA uptake as well as improved diastolic function
(Hammer et al., 2008; Viljanen et al., 2009).
Reducing plasma lipids to reduce lipid uptake and converting
oxidation tomore glucose and less FAmight be amethod to treat
patients with lipotoxic and ischemic heart failure. Agents that
inhibit FA oxidation have been used for angina. Perhexiline is
a drug that blocks carnitine palmitoyl transferase-1 (CPT-1)
and CPT-2 and mitochondrial FA uptake. Heart-failure patients
with both ischemic and nonischemic heart failure treated with
perhexiline had improved cardiac function and symptoms (Lee
et al., 2005; Tuunanen et al., 2008). Trimetazidine, another
drug thought to reduce FA oxidation, modestly improved heart
function and also improved overall insulin sensitivity in patientswith idiopathic dilated ischemia (Tuunanen et al., 2008). In
contrast, depletion of circulating FAs in order to reduce FA
uptake and storage into TGs did not affect cardiac function in
patients with heart failure (Halbirk et al., 2010)—and in one study
actually was harmful (Tuunanen et al., 2006). This latter interven-
tion study measuring myocardial function and metabolism
before and after administration of acipimox, a nicotinic acid-
like inhibitor of lipolysis, was an acute study in which in each
subject served as his or her own control. Therefore, the overall
benefit of reducing FA oxidation in heart failure is still unclear
andmight require studies in which the etiology of the heart failure
is more precisely defined.
Conclusions
Although lipid-induced cardiac toxicity clearly can be created,
a number of clinical and experimental issues await clarification.
We do not know about the exact clinical implications of this path-
ophysiologic phenomenon. Is it really a primary cause of cardiac
dysfunction in patients with type 2 diabetes and metabolic
syndrome? If so, does this occur because of unregulated cardiac
uptake of FAs or reduced FA oxidation? If the latter, one could
then postulate that in the setting of ischemia and afterload-
induced heart failure, reduced FA oxidation should also promote
accumulation of toxic lipids. Or, as has been postulated in
ischemia, does a disproportionate use of FAs create toxicity?
Which lipids are really toxic and which pathways are induced
that lead to cellular dysfunction? A marriage of human and
animal experimentation should sort out the answers to many of
these questions in the next decade.
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